Sulfathiazole (2 sulfanilamide-thiazole) is the newest of the group of chemotherapeutic agents employed in the treatment of pneumococcic pneumonia. Its efficacy in pneumonia is being thoroughly investigated in many of the larger hospitals in this country. Clinical reports1 and our own results show that in its therapeutic effects sulfathiazole in pneumonia compares favorably with sulfapyridine and that it is preferable to sulfanilamide. It also has the added advantage of being less toxic and less likely to cause some of the complications encountered after the use of either of these other drugs. Since sulfathiazole is still on trial it is important to record any of the complications or sequelae that may arise from its use. Reinhold, Flippin and Schwartz2 observed that sulfathiazole is not as readily reabsorbed from the kidney tubules as are sulfapyridine and sulfanilamide. Gross, Cooper and Scott3 reported the formation of sulfathiazole crystals in the
Loewenberg SA, Sloane NG, Chodoff P. SULFATHIAZOLE URINARY CALCULI IN THE KIDNEYS, URETERS AND BLADDER: IN THE ABSENCE OF MARKED URINARY CHANGES FOLLOWING SULFATHIAZOLE THERAPY. JAMA. 1940;115(24):2069–2071. doi:10.1001/jama.1940.72810500001010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: